Compare MDXG & PLSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MDXG | PLSE |
|---|---|---|
| Founded | 2006 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.2B |
| IPO Year | N/A | 2016 |
| Metric | MDXG | PLSE |
|---|---|---|
| Price | $7.07 | $15.01 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 1 |
| Target Price | $11.00 | ★ $22.00 |
| AVG Volume (30 Days) | ★ 741.2K | 186.0K |
| Earning Date | 10-29-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.27 | N/A |
| Revenue | ★ $393,442,000.00 | $86,000.00 |
| Revenue This Year | $19.13 | N/A |
| Revenue Next Year | $2.11 | $1,002.94 |
| P/E Ratio | $25.92 | ★ N/A |
| Revenue Growth | ★ 14.77 | N/A |
| 52 Week Low | $5.79 | $12.56 |
| 52 Week High | $9.71 | $25.00 |
| Indicator | MDXG | PLSE |
|---|---|---|
| Relative Strength Index (RSI) | 51.32 | 55.35 |
| Support Level | $6.91 | $14.33 |
| Resistance Level | $7.45 | $15.96 |
| Average True Range (ATR) | 0.24 | 0.73 |
| MACD | 0.01 | 0.23 |
| Stochastic Oscillator | 53.50 | 61.27 |
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed-Field Ablation or nsPFA technology when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled.